Clinical Trial Update: MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating MESO-CAR T cell therapy for relapsed and refractory epithelial ovarian cancer. Status not disclosed in provided snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• MESO-CAR T cells (CAR T cell therapy targeting mesothelin)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: UNKNOWN